These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18427543)

  • 21. Obesity; epiphenomenon or cause of metabolic syndrome?
    Lois K; Young J; Kumar S
    Int J Clin Pract; 2008 Jun; 62(6):932-8. PubMed ID: 18479286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population.
    Mancia G; Bombelli M; Facchetti R; Madotto F; Corrao G; Trevano FQ; Giannattasio C; Grassi G; Sega R
    J Hypertens; 2008 Aug; 26(8):1602-11. PubMed ID: 18622239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity: a central risk and cardiovascular target of the cardiometabolic syndrome.
    Frohlich ED
    J Cardiometab Syndr; 2008; 3(3):147-8. PubMed ID: 18983330
    [No Abstract]   [Full Text] [Related]  

  • 24. [The numbers of patients with endocrine disorders are increasing. Who will be responsible for them in the future?].
    Klaus M
    MMW Fortschr Med; 2006 Mar; 148(9):25-6. PubMed ID: 16566388
    [No Abstract]   [Full Text] [Related]  

  • 25. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed.
    D'Adamo E; Santoro N; Caprio S
    Endocrinol Metab Clin North Am; 2009 Sep; 38(3):549-63. PubMed ID: 19717004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P
    Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Metabolic syndrome. What is the definition in practice?].
    Schindler B
    Med Monatsschr Pharm; 2006 Dec; 29(12):463-4. PubMed ID: 17220046
    [No Abstract]   [Full Text] [Related]  

  • 28. Stemming the obesity-diabetes epidemic: lifestyle changes and therapeutics.
    Schrier RW; Bogaert YE
    Nat Clin Pract Nephrol; 2008 Sep; 4(9):486-7. PubMed ID: 18665143
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
    Brunero S; Lamont S; Fairbrother G
    Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Obesity and the metabolic syndrome: a new epidemic].
    Bordier L; Cremades S; Dupuy O; Mayaudon H; Bauduceau B
    Bull Acad Natl Med; 2009 Jun; 193(6):1289-300; discussion 1301. PubMed ID: 20120160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Brzozowska MM; Ostapowicz G; Weltman MD
    J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus.
    Hayden MR; Sowers JR
    J Cardiometab Syndr; 2008; 3(3):129-31. PubMed ID: 18983326
    [No Abstract]   [Full Text] [Related]  

  • 34. The metabolic syndrome and cardiovascular risk: implications for clinical practice.
    Eddy DM; Schlessinger L; Heikes K
    Int J Obes (Lond); 2008 May; 32 Suppl 2():S5-10. PubMed ID: 18469838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
    Cannon CP
    Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
    Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
    Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
    Cybulska B; Kłosiewicz-Latoszek L
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II45-50. PubMed ID: 19813336
    [No Abstract]   [Full Text] [Related]  

  • 38. The metabolic syndrome in Japan.
    Fujita T
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S15-8. PubMed ID: 18580861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolic syndrome--from insulin resistance to obesity and diabetes.
    Gallagher EJ; LeRoith D; Karnieli E
    Endocrinol Metab Clin North Am; 2008 Sep; 37(3):559-79, vii. PubMed ID: 18775352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.